

Ė

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Li et al.

Appl. No.: 10/791,905

Filed: March 4, 2004

For: Human G-Protein Chemokine Receptor (CCR5) HDGNR10 Confirmation No.: 3954

Art Unit: 1649

Examiner: Ulm, John D.

Atty. Docket: 1488.115000P/EKS/HCC

## Fourth Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(c)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Forms PTO/SB/08A and PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Fourth Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Third Supplemental Information Disclosure Statement filed on June 1, 2005 in connection with the above-captioned application.

A copy of document **AT67** is submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), a copy of U.S. patent, document **AK4**, cited on the attached Form PTO/SB/08A is not submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based

44

on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

- 1. Statement under 37 C.F.R. 1.704(d). Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.
- 2. Filing under 37 C.F.R. § 1.97(b). This Information Disclosure Statement is being filed within three months of the date of filing of a national application other than a continued prosecution application (CPA), OR within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, OR before the mailing date of a first Office Action on the merits OR before the mailing of a first Office Action after the filing of a request for continued examination under 37 C.F.R. § 1.114. No statement or fee is required.

- - a. Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
  - b. Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
- 4. Filing under 37 C.F.R. § 1.97(d) This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee.

Enclosed find our PTO-2038 Credit Card Payment Form in the amount of

	\$ i	n payment of the fee under 37 C.F.R. § 1.17(p); in addition:
	□ a.	Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each
		item of information contained in this Information Disclosure
		Statement was first cited in any communication from a foreign
		patent office in a counterpart foreign application not more than
		three months prior to the filing of this Information Disclosure
		Statement. 37 C.F.R. § 1.97(e)(1).
	□ b.	Statement under 37 C.F.R. § 1.97(e)(2). I hereby state that no item
		of information in this Information Disclosure Statement was cited
		in a communication from a foreign patent office in a counterpart
		foreign application and, to my knowledge after making reasonable
		inquiry, was known to any individual designated in 37 C.F.R. §
		1.56(c) more than three months prior to the filing of this
		Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
<u></u> 5.	The documer	nt(s) was/were cited in a search report by a foreign patent office in a
	counterpart f	Foreign application. Submission of an English language version of
	the search rep	port that indicates the degree of relevance found by the foreign office
	is provided	in satisfaction of the requirement for a concise explanation of
	relevance. 11	38 OG 37, 38.
<u> </u>		eplanation of the relevance of the non-English language document(s) w in accordance with 37 C.F.R. § 1.98(a)(3).
	• •	

☐ 6.	A concise explanation of the relevance of the non-English language document(s) appears below in accordance with 37 C.F.R. § 1.98(a)(3).
<b>7</b> .	Copies of the documents were cited by or submitted to the Office in an IDS that
	complies with 37 C.F.R. § 1.98(a)-(c) in Application No, filed
	, which is relied upon for an earlier filing date under 35 U.S.C.
	§ 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).
□ 8.	It is expected that the examiner will review the prosecution and cited art in the
	parent application no(s). in accordance with MPEP 2001.06(b), and indicate in
	the next communication from the office that the art cited in the earlier
	prosecution history has been reviewed in connection with the present application.
	It is respectfully requested that the Examiner initial and return a copy of the
enclos	ed IDS Forms, and indicate in the official file wrapper of this patent application
that th	e documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Wilenellails.

Helene C. Carlson Agent for Applicants Registration No. 47,473

Date: April 25, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

486681\_1.DOC

Equivalent of Form PTO/SB/08A (07-05)
Approved for use through 07/31/2006.
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

FOURTH SUPPLEMENTAL

stitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

of

 Complete if Known

 Application Number
 10/791,905

 Filing Date
 March 4, 2004

 First Named Inventor
 Yi Li

 Art Unit
 1649

 Examiner Name
 Ulm, John D.

 Attorney Docket Number
 1488.115000P/EKS/HCC

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (If Known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	AK4	6,075,181	06/13/2000	Kucherlapati et al.		
		-				
		-		1.00		

		Fo	REIGN PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document		
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
			٠			<u> </u>
						$oldsymbol{ol}}}}}}}}}}}}}}}}}$

486696\_1.DOC

Examiner	Date	
Signature	Considered	
		<u> </u>

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant: 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). The patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 'Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Stitute for form 1449/PTO				Со	Complete if Known		
E01	ID ID IT C	TIDNY 1		Application Number	10/791,905		
			EMENTAL	Filing Date	March 4, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				riist Nameu mvemoi	Yi Li		
				Art Unit	1649		
(Use as many sheets as necessary)			s necessary)	Examiner Name	Ulm, John D.		
Sheet	1	of	1	Attorney Docket Number	1488.115000P/EKS/HCC		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published					
	AT67	Vila-Coro, A.J., et al., "HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization," <i>Proc. Natl. Acad. Sci. USA 97</i> :3388-3393, The National Academy of Sciences (March 2000)					
		·					
		·					
		•					

486699\_1.DOC

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.